Beck Bode LLC’s Inovio Pharmaceuticals INO Stock Holding History

Beck Bode LLC’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,435	Closed	-$33.8K	–	150
2023 Q1	$33.8K	Buy	3,435 +1,166	+51%	+$19.9K	0.01%	139
2022 Q4	$42.5K	Buy	+2,269	New	+$51.4K	0.01%	181
2021 Q3	–	Sell	-242	Closed	-$27K	–	180
2021 Q2	$27K	Buy	+242	New	+$23.2K	0.01%	176
2020 Q4	–	Sell	-159	Closed	-$22K	–	138
2020 Q3	$22K	Buy	+159	New	+$33.2K	0.01%	161

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Beck Bode LLC's INO Position: Q2 2023 in Review

Beck Bode LLC sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 3,435 shares — an estimated $33.8K sold.

Beck Bode LLC first reported a position in INO in Q3 2020 and held it in 4 quarters. The position peaked at $42.5K in Q4 2022. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Beck Bode LLC reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Beck Bode LLC sold 3,435 Inovio Pharmaceuticals shares in Q2 2023, an estimated $33.8K.
Beck Bode LLC first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Beck Bode LLC's Inovio Pharmaceuticals position peaked at $42.5K in Q4 2022.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Beck Bode LLC's 13F filing for Q2 2023, filed 10 Aug 2023.